Additional patent protection for Ygalo granted in Europe until 2032
Stockholm - March 21, 2017 - Oncopeptides AB (Nasdaq Stockholm; ONCO) announced today that the European Patent Office (EPO) recently issued a notice that they intend to grant an additional European patent to Oncoeptides AB.The patent (EP2701720) covers inter alia the lyophilized formulation of Ygalo that is intended to be launched. The patent can be validated in 38 European countries. The patents will expire in April 2032."We are pleased to have received this patent notice. It is in line with expectation but has now also been confirmed. It clearly increases Ygalo’s future commercial